Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $17.80

Calliditas Therapeutics AB (publ) (NASDAQ:CALT)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $17.80, but opened at $18.43. Calliditas Therapeutics AB (publ) shares last traded at $18.36, with a volume of 1,530 shares changing hands.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Trading Up 3.1 %

The company has a fifty day moving average of $21.26 and a two-hundred day moving average of $20.61. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The stock has a market capitalization of $546.94 million, a price-to-earnings ratio of -11.20 and a beta of 1.50.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last posted its earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. The firm had revenue of $42.45 million during the quarter, compared to analyst estimates of $36.24 million. During the same period in the previous year, the company earned ($0.01) EPS. On average, research analysts expect that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

Several institutional investors and hedge funds have recently added to or reduced their stakes in CALT. Jane Street Group LLC acquired a new stake in Calliditas Therapeutics AB (publ) in the 1st quarter worth approximately $221,000. Tower Research Capital LLC TRC lifted its holdings in Calliditas Therapeutics AB (publ) by 1,270.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock worth $51,000 after purchasing an additional 3,112 shares during the last quarter. Deutsche Bank AG increased its position in Calliditas Therapeutics AB (publ) by 26.5% in the 1st quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock worth $2,170,000 after buying an additional 18,978 shares during the period. Finally, Optiver Holding B.V. bought a new position in Calliditas Therapeutics AB (publ) in the 4th quarter worth approximately $25,000. 2.83% of the stock is currently owned by institutional investors and hedge funds.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.